PURPOSE: The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV). METHODS: Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage breast cancer scheduled to receivedadjuvant anthracycline-based chemotherapy were categorized as being at low (level 0) or high-risk (level 1) for CINV. Prior to the first cycle of chemotherapy, low-risk patients received ondansetron and dexamethasone, while high-risk level 1 patients also received aprepitant. For subsequent cycles, patients who experienced CINV had their antiemetics changed in a stepwise manner to level 2 (extended-duration dexamethasone) or level 3 (extended-duration dexamethasone and low-dose olanzapine). RESULTS: The study enrolled 152 patients who received 484 cycles ofchemotherapy. Forty patient cycles were classified as low risk (level 0) compared to 201, 162 and 81 that were classified as high-risk levels 1, 2 and 3, respectively. Complete control of acute and delayed vomiting was comparable and was achieved in over 85 % of patients across all risk levels (p = 0.56 and p = 0.99). In contrast, complete control of acute and delayed nausea was reduced in risk levels 1 to 3 compared to level 0 (acute = 51.2, 58.0, 45.7 vs. 70.0 %; p = 0.013)-(delayed = 32.8, 45.7, 34.6 vs. 62.5 %; p < 0.001). CONCLUSIONS: Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control.
RCT Entities:
PURPOSE: The objective of this exploratory analysis was to determine if individual patient risk factors could be used to optimize chemotherapy-induced nausea and vomiting (CINV). METHODS: Through validated risk prediction models which quantify patient risk factors, 152 patients with early-stage breast cancer scheduled to received adjuvant anthracycline-based chemotherapy were categorized as being at low (level 0) or high-risk (level 1) for CINV. Prior to the first cycle of chemotherapy, low-risk patients received ondansetron and dexamethasone, while high-risk level 1 patients also received aprepitant. For subsequent cycles, patients who experienced CINV had their antiemetics changed in a stepwise manner to level 2 (extended-duration dexamethasone) or level 3 (extended-duration dexamethasone and low-dose olanzapine). RESULTS: The study enrolled 152 patients who received 484 cycles of chemotherapy. Forty patient cycles were classified as low risk (level 0) compared to 201, 162 and 81 that were classified as high-risk levels 1, 2 and 3, respectively. Complete control of acute and delayed vomiting was comparable and was achieved in over 85 % of patients across all risk levels (p = 0.56 and p = 0.99). In contrast, complete control of acute and delayed nausea was reduced in risk levels 1 to 3 compared to level 0 (acute = 51.2, 58.0, 45.7 vs. 70.0 %; p = 0.013)-(delayed = 32.8, 45.7, 34.6 vs. 62.5 %; p < 0.001). CONCLUSIONS: Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: George Dranitsaris; Nathaniel Bouganim; Carolyn Milano; Lisa Vandermeer; Susan Dent; Paul Wheatley-Price; Jenny Laporte; Karen-Ann Oxborough; Mark Clemons Journal: J Support Oncol Date: 2013-03
Authors: N Bouganim; G Dranitsaris; S Hopkins; L Vandermeer; L Godbout; S Dent; P Wheatley-Price; C Milano; M Clemons Journal: Curr Oncol Date: 2012-12 Impact factor: 3.677
Authors: P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla Journal: Ann Oncol Date: 2014-03-07 Impact factor: 32.976
Authors: Kednapa Thavorn; Doug Coyle; Jeffrey S Hoch; Lisa Vandermeer; Sasha Mazzarello; Zhou Wang; George Dranitsaris; Dean Fergusson; Mark Clemons Journal: Support Care Cancer Date: 2017-03-09 Impact factor: 3.603
Authors: Sylvia L Crowder; Aasha I Hoogland; Taylor L Welniak; Elizabeth A LaFranchise; Kristen M Carpenter; Daneng Li; Daniel M Rotroff; Arshiya Mariam; Christine M Pierce; Stacy M Fischer; Anita Y Kinney; Thi Dong-Binh Tran; Farzaneh Rastegari; Donna L Berry; Martine Extermann; Richard D Kim; Danielle B Tometich; Jane C Figueiredo; Jameel Muzaffar; Shahla Bari; Kea Turner; George M Weinstock; Heather S L Jim Journal: Cancer Date: 2021-10-13 Impact factor: 6.860
Authors: Komal Singh; Keenan Pituch; Qiyun Zhu; Haiwei Gu; Brenda Ernst; Cindy Tofthagen; Melanie Brewer; Kord M Kober; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022-03-02 Impact factor: 2.760
Authors: Komal P Singh; Kord M Kober; Brenda Ernst; Jasgit Sachdev; Melanie Brewer; Qiyun Zhu; Haiwei Gu; Michele Melisko; Steven M Paul; Bruce A Cooper; Marilyn Hammer; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022 May-Jun 01 Impact factor: 2.760
Authors: M Clemons; G Dranitsaris; M Sienkiewicz; S Sehdev; T Ng; A Robinson; M Mates; T Hsu; S McGee; O Freedman; V Kumar; D Fergusson; B Hutton; L Vandermeer; J Hilton Journal: Breast Date: 2020-11-10 Impact factor: 4.380